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INTRODUCTION
Zika virus is part of the virus family Flaviviridae that can be carried by Aedes 
mosquitoes.1,2,3 Since 2015, the virus has spread quickly in the tropical regions of the 
Americas.4,5,6 Transmission of Zika virus can occur through serum, prenatally, or 
sexually.7,8,9 The majority of infected adults are asymptomatic.10,11 If they do present 
symptoms, the symptoms commonly are mild and include joint pain, conjunctivitis, and rash 
or a fever that lasts two to seven days.12,13 However, the infection can have severe 
consequences when transmitted perinatally.5,9,14 In March 2016, the World Health 
Organization (WHO) reported that Zika virus infections during pregnancy can cause 
neonatal microcephaly and other congenital birth disorders.15 Thus, prevention of Zika 
infection during pregnancy is of high importance. As of July 5th 2017, the Centers for 
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Disease Control and Prevention (CDC) had documented a total of 663 symptomatic Zika 
cases in the United States (U.S.) and territories.16
The WHO has listed developing a Zika vaccine as a top research priority.17 Vaccination is 
among the most successful public health strategies, and is a priority for prevention of 
congenital Zika, given the severity of the disease and that mosquito-borne infections are hard 
to prevent through other interventions.18 Until a vaccine is available, women will need to 
rely on other methods to prevent sexual or mosquito transmission.19
Given the severity of neonatal infection and the promise of a vaccine, it is timely to assess 
pregnant women’s attitudes about Zika prevention. Previous research has found gaps in 
knowledge about transmission, including sexual transmission, and vaccine acceptability 
ranged from 21% of pregnant women in Greece to 56% of female college students in 
Virginia.20, 21 We extended this research by drawing on a national sample of pregnant 
women in the U.S. to understand: 1) pregnant women’s attitudes and knowledge about Zika 
virus, 2) factors associated with perceptions of their ability to implement behavioral 
strategies to prevent Zika acquisition during pregnancy, and 3) factors associated with their 
willingness to receive a Zika vaccine if one were developed and available.
MATERIALS AND METHODS
A U.S. national sample of pregnant women (N = 362) completed an online survey 
addressing attitudes about health during pregnancy. Responses were collected from 
November 8th to November 16th, 2016. Eligibility criteria included being pregnant and over 
the age of 18 years, living in the U.S., and speaking Spanish or English. Participants were 
enrolled through Survey Sampling International (SSI)22 a survey research company that 
maintains a national panel of over four million individuals in the United States. Respondents 
were compensated $10.00 worth of SSI panel account incentives. A study information sheet 
was presented and participants indicated informed consent to participate by initiating survey 
responses. All recruitment and study procedures were approved by the Columbia University 
Medical Center Institutional Review Board.
Questionnaire
Socio-demographic information included age category, race-ethnicity, relationship status, 
pregnancy and sexually transmitted infection (STI) history. Each woman was asked if she 
had lived in or traveled to a place where she could acquire a Zika infection. We also asked 
participants to indicate their general perceived level of Zika knowledge on a four-point scale, 
and worry about Zika on a three-point Likert-type scale.
Race-ethnicity was coded as Hispanic, non-Hispanic White, non-Hispanic African-
American, non-Hispanic Other, and non-Hispanic multi-racial. For purposes of predictive 
analyses, the five women who were non-Hispanic multi-racial were excluded. Relationship 
with the father of the baby (FOB) was collapsed as follows: being married or living together, 
being together but not living together, and not being together.
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We assessed factual knowledge of Zika with eight statements for which the response options 
were “yes”, “no”, or “I don’t know”. Six statements asked about the route of transmission of 
the virus (i.e., mosquito bites, sharing drinks, perinatal acquisition, shaking hands, sexual 
transmission, and sneezing). One statement assessed the severity of the virus for adults (i.e., 
having mild symptoms) and one additional question relating to sexual transmission (i.e., 
men can have it remain in semen for an unknown period). “I don’t know” responses were 
scored as incorrect.
After completion of the knowledge portion, the following brief informational paragraph was 
provided: If a pregnant woman gets Zika either through a mosquito bite or from sex, the 
baby can have serious developmental problems including a small head, and brain and eye 
abnormalities. At the moment, there is no treatment for Zika for a pregnant women and no 
vaccine to prevent infection.
Six subsequent items measured how difficult it would be (not at all hard, somewhat hard, 
very hard) for participants to prevent Zika during pregnancy using behavioral strategies (i.e., 
abstaining from sex, using condoms, not traveling to an area with Zika, their partner not 
traveling into an area with Zika, using mosquito repellant, wearing long pants and sleeves). 
In order to evaluate the difficulty of implementing the six behavioral strategies, the strategies 
were summed.
Three items assessed attitudes about vaccines for Zika (i.e., importance, vaccine strategy, 
vaccine acceptability). For predictive models, we dichotomized vaccine importance into very 
important and somewhat important versus not at all important.
Statistical Analysis
All statistical analyses were conducted using SAS 9.4 (SAS Institute Inc. Cary, NC, U.S.A). 
Using linear models, we evaluated each predictor in bivariate models for associations with 
perceptions that the behavioral strategies were hard to do. Those that were significant at p < 
0.10 were retained for a multivariable linear model with backwards elimination, for which 
the p was set at < 0.05. In order to evaluate vaccine acceptability, we compared yes to no/not 
sure. Using logistic regression models, we evaluated the association of each predictor with 
vaccine acceptability in bivariate models. Those that were significant at p < 0.10 were 
retained for a multivariable logistic regression with backwards elimination, for which the p 
was set at < 0.05.
As always with self-completed surveys, there was occasionally missing data. The number of 
missing responses did not exceed eight for all items; thus, the sample size of missing 
responses is not reported for each item in the results.
RESULTS
Sample
The majority of women (91%) were married or living with the father of the baby, 67% were 
25–35 years, and 65% were non-Hispanic Caucasian. (Table 1) The respondents represented 
43 states and Puerto Rico. Seventy-two percent reported that they either had not lived/
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traveled or were not sure whether they had lived/traveled in an area with Zika, and 28% 
reported they had. Eight percent had “never heard about it”, 20% had “heard about it but 
didn’t know much about it”, 43% thought they knew “a little bit”, and 30% thought they 
“knew a lot”. Perceived knowledge was dichotomized into knowing less (i.e. “having never 
heard about it”/“having heard about it but not knowing much about it”/“knowing a little bit 
about it”) (70%), versus knowing a lot (30%). Overall, 26% reported not being worried 
about Zika, and 74% reported being very or somewhat worried.
The mean factual knowledge score was 5.0 out of 8 (SD = 2.09). Most answered correctly 
that mosquitos transmit Zika (87% correct), and most did not know that the virus could 
remain in the semen for an unknown period of time (49% correct) (Table 2). Participants’ 
perceived knowledge was associated with their factual knowledge (F (1, 352) = 29.40; p < 
0.01); more factual knowledge was associated with greater perceived knowledge.
Behavioral strategies
Of the six behavioral strategies, the strategy most frequently endorsed as “very hard” was 
“not traveling themselves to a place where the mosquitos have Zika” (31%) and the one that 
women least frequently endorsed as “very hard” was “wearing long pants and sleeves” 
(18%). (Table 3). The mean score was 4.9 (SD = 3.7; range = 0 to 12). A score of 0 indicates 
that all items were rated as not at all hard to do and a score of 12 indicates that all items 
were rated as very hard to do. Fifty-four (16%) of the participants thought that all strategies 
were not at all hard to do; nine (3%) thought that all of the strategies were very hard to do.
In bivariate models, the following variables were not significantly associated with the degree 
to which the women thought the behavioral strategies would be hard to do: age, having been 
previously pregnant, race-ethnicity, and factual knowledge. The following were associated 
with the degree to which the women reported that the behavioral strategies would be hard to 
do: having an STI history; having lived/traveled in an area with Zika; believing they knew a 
lot about Zika; being worried about Zika (Table 4). The following remained in the 
multivariable model; those who had lived/traveled in an area with Zika, were worried, and 
who had been diagnosed with a STI, were more likely to report that the behavioral strategies 
were hard to do (Table 4). The mean and standard deviation of perceptions that the 
behavioral strategies would be hard to do by group are as follows: lived/traveled to an area 
with Zika (M=7.7, SD=3.0) versus not having traveled/lived (M=3.8, SD=3.3); worried 
about Zika (M=5.6, SD=3.6) versus not being worried (M=2.8, SD=2.9), and STI history 
(M=6.5, SD=3.8) versus no STI history (M=4.4, SD=3.5).
Vaccine attitudes and acceptability
With regards to vaccination, 72% thought the development of a Zika vaccine was very 
important, 25% thought it was somewhat important, and 3% thought it was not important. A 
universal vaccine strategy (all women and all men between 14 and 40 years of age) was 
selected by 38% of women, with an additional 20% supporting a gender-specific universal 
strategy. The other strategies were endorsed by the following percentage of participants: 
22% chose “women and male partners of women who are planning to get pregnant within 
the next year”, 6% chose “only women who are planning to get pregnant” within the next 
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year, 6% chose “only women whose male partners have Zika”, 8% chose “No one, I don’t 
believe in vaccines”. When asked if a safe and effective Zika vaccine were available today, 
72% said they would agree to get it, 15% said they would decline, and 14% were not sure.
Age, race-ethnicity, having ever been pregnant and vaccine strategy were not related to 
vaccine acceptability. In bivariate models, a history of STI, having lived/traveled in an area 
with Zika, believing they knew a lot about Zika, greater factual knowledge, being worried 
about Zika, considering it important to develop a Zika vaccine, and finding it hard to do 
behavioral preventative strategies, were associated with likelihood of accepting the vaccine 
at p < .10. (Table 5). The following remained in the multivariable model; considering it 
important to develop a Zika vaccine, having lived/traveled in an area with Zika, believing 
they knew about Zika, and being worried about Zika (Table 5). The differences in vaccine 
acceptability by these predictors was as follows: considering it important to develop a Zika 
vaccine (73%) versus not believing it was important (18%), lived/traveled to an area with 
Zika (89%) versus not having traveled/lived (65%); believing they knew a lot about Zika 
(85%) versus not believing they knew a lot (66%); and being worried about Zika (78%) 
versus those who were not worried about Zika (55%).
DISCUSSION
WHO continues to view Zika as a public health issue that needs a long-term programmatic 
approach.23 In order to modulate the course of Zika and potentially eradicate it, the 
development of an effective vaccine remains one of the best options.17,18,24 However, until a 
vaccine is developed and available, other preventative strategies will need to be used.
A necessary, although not sufficient, factor to foster preventive behaviors and vaccine uptake 
is adequate knowledge about one’s susceptibility to the disease and the severity of its 
consequences. Our results are consistent with those of pregnant women in Greece, in that 
11%–13% did not understand mosquito transmission. 20 There is even a greater lack of 
understanding of sexual transmission and that it is unknown how long their male partner can 
transmit the virus.20,21 Other studies have suggested that health care providers may also be 
insufficiently informed.25 The experience with human papillomavirus vaccine uptake in the 
U.S. has demonstrated the importance of health care provider support for vaccination in 
order to foster uptake.26 Thus, addressing knowledge gaps among patients and providers will 
be crucial to foster Zika vaccine uptake. One study found that the most frequent source of 
information about Zika came from television or radio; it will be important to determine the 
best methods for communicating with the public.20
It is well known that factors, such as self-efficacy, are necessary to engage in preventive 
health behaviors.27, 28 For each of the preventive strategies assessed, half or more of the 
women reported that it would be somewhat hard or very hard to do. Women who viewed 
themselves as vulnerable (being worried, having lived/traveled in a Zika area, and having a 
history of an STI) were more likely to view the behavioral strategies as hard to do. It is 
possible that the sense of vulnerability made them more cautious in assessing their ability to 
perform the strategies. Other studies have shown that few people engage in behaviors to 
prevent mosquito bites (16% of pregnant women used clothes and 53% used repellant).20 
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These numbers may be greater during a Zika epidemic or under threat from another 
mosquito-borne infection.
Our sample of pregnant women in the U.S. supported Zika vaccine development. The most 
commonly endorsed strategy by these participants was a universal strategy for both men and 
women of child-bearing age. Given that perceived severity of an infection is typically critical 
to vaccine uptake; linking the vaccination to prevention of neonatal disease will be 
important. Although research that examined acceptability of HPV vaccine prior to vaccine 
availability overestimated the subsequent uptake, many of the barriers in the U.S. have been 
structural and systemic given the U.S. reliance on school mandates.29 In contrast, HPV 
vaccine uptake has been much higher in Australia, which uses school-based 
immunization.30,31 Thus, the imperfect relationship between acceptability and uptake will 
vary for each specific vaccine and its context. However, the results of this study suggest that 
pregnant women are interested in a Zika vaccine and find a Zika vaccine personally 
acceptable.
The findings for vaccine acceptability differed from those for behavioral strategies in that 
women who perceived themselves as vulnerable (traveling/living in an area with Zika, being 
worried) reported being likely to get a vaccine. It appears that women with similar 
characteristics both feel that the behavioral strategies would be hard to do and that they 
would accept a vaccine. A concern could be raised about risk compensation, i.e., that 
vaccination could lead to a reduction in other preventive strategies, which in turn might 
reduce the impact of vaccination.32, 33 This concern has been mentioned in relation to other 
vaccines such as the HPV vaccine (e.g. increased risky sexual behavior or lack of pap smear 
screening following the HPV vaccine another reference), a Lyme disease vaccine, and HIV 
vaccination.34,35 However, there is no current scientific evidence to support this concern.
Limitations of the study were primarily related to the convenience sample of women living 
in relatively low risk areas. In addition, we focused on the severity of the illness to adults, 
not to neonates. However, these limitations were balanced against a large sample of pregnant 
women from 43 states and Puerto Rico, and the timely assessment of these women’s 
knowledge, attitudes, and willingness to engage in behaviors related to Zika prevention. 
Future research should specifically target women from high-risk areas and should also aim 
to compare the attitudes of pregnant women with and without Zika.
CONCLUSIONS
This study has increased our knowledge about pregnant women’s understanding of Zika 
virus and their perceptions about preventative options. We demonstrated a gap between 
pregnant women’s worry about Zika (74%) and their knowledge, both perceived (only 30% 
thought they knew a lot) and factual (mean of 5.0 out of 8 items). Thus, we need to engage 
health care providers (who themselves may have knowledge gaps) in playing an active role 
in ensuring pregnant women are educated about the risks and severity of Zika infection, and 
the methods for preventing transmission. Pregnant women also will need support to engage 
in the existing behavioral options to reduce the risk of acquisition. Their concerns about 
implementing those strategies and the acceptability of a vaccine suggest that vaccine 
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development should remain a priority. Once a vaccine is available, there will need to be 
educational campaigns to strengthen the relationship between acceptability and uptake.
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HIGHLIGHTS
• Most (74%) pregnant women expressed concerns about the Zika virus.
• Low perceived knowledge of Zika corresponded to low factual knowledge.
• Developing a Zika vaccine was very important to the majority (72%) of 
respondents.
• Women (38%) supported a universal strategy that would vaccinate men and 
women.
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Table 1
Sociodemographic Characteristics
Characteristic N (%)
Total N = 362
Relationship with father of the baby
Married/living with father of the baby 327 (91%)
In a relationship but not living together 17 (5%)
Not in a relationship 16 (4%)
Age group
18–24 77 (21%)
25–30 140 (39%)
31–35 101 (28%)
≥ 35 42 (12%)
Race-ethnicity
White Non-Hispanic 237 (65%)
African American 27 (7%)
Hispanic 77 (21%)
Other 21 (6%)
Pregnancy History
Yes 254 (71%)
No 104 (29%)
STI History
No 277 (77%)
Yes 82 (23%)
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Table 2
Percent Correct for Knowledge Items
Knowledge Item % correct
Mosquito transmission 87%
From mother to her unborn baby 69%
Adults have no/mild symptoms 65%
Shaking hands (correct = no) 65%
From sharing drinks (correct = no) 60%
Through sex 53%
From sneezing on someone (correct = no) 51%
Virus remain in the semen for an unknown period of time 49%
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Table 3
Behavioral Strategy (Number and Percent Endorsing)
Behavioral Strategy Very hard
N (%)
Somewhat hard
N (%)
Not at all hard
N (%)
Not traveling to Zika area 110 (31%) 74 (21%) 176 (49%)
Partner not travel to Zika area 66 (19%) 126 (35%) 164 (46%)
Abstain from sex 100 (28%) 155 (44%) 98 (28%)
Use condoms 87 (25%) 111 (31%) 155 (44%)
Wearing long sleeves and pants 64 (18%) 136 (39%) 151 (43%)
Using mosquito repellant 86 (24%) 91 (25%) 180 (50%)
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Table 4
Significant Predictors of Behavioral Strategies
Bivariate Analysis Multivariate Analysis
Significant Predictors F value P F value P
History of STI (yes vs. no) F(1,340)= 22.06 ** F(1,337) = 5.80 *
Lived/traveled to a Zika area (yes vs. no) F(1,343) = 100.53 ** F(1,337) = 52.89 **
Perceived Zika knowledge (a lot vs. less) F(1,343) =4.24 * -
Worried about Zika (yes vs. no) F(1,343) = 42.94 ** F(1,337)= 18.41 **
*p < .05
**p < .01
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Table 5
Significant Predictors of Vaccine Acceptability
Bivariate Analysis Multivariate Analysis
Significant Predictors OR (95% CI) AOR (95% CI)
History of STI (yes vs. no) 2.2 (1.2 – 4.2)* -
Lived/traveled to a Zika area (yes vs. no) 4.4 (2.2 – 8.6)** 2.7 (1.3 – 5.5)**
Perceived Zika knowledge (a lot vs. less) 3.0 (1.7 – 5.4)** 2.9 (1.5 – 6.0)**
Factual Zika knowledge 1.2 (1.1 – 1.3)** -
Worried about Zika (yes vs. no) 2.8 (1.7 – 4.6)** 1.8 (1.0–3.1) *
Hard to do behavioral strategies 1.1 (1.0 – 1.2)* -
Considering vaccine important (yes vs. no) 12.4 (2.6 – 58.6)** 10.8(2.1 – 54.3)**
*p < .05
**p < .01
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